MA35460B1 - Composés et compositions en tant qu'inhibiteurs de kinase c-kit - Google Patents

Composés et compositions en tant qu'inhibiteurs de kinase c-kit

Info

Publication number
MA35460B1
MA35460B1 MA36864A MA36864A MA35460B1 MA 35460 B1 MA35460 B1 MA 35460B1 MA 36864 A MA36864 A MA 36864A MA 36864 A MA36864 A MA 36864A MA 35460 B1 MA35460 B1 MA 35460B1
Authority
MA
Morocco
Prior art keywords
compounds
kinase inhibitors
compositions
kit kinase
kit
Prior art date
Application number
MA36864A
Other languages
English (en)
Inventor
Valentina Molteni
Hank Michael James Petrassi
Xiaolin Li
Xiaodong Liu
Jon Loren
Juliet Nabakka
Bao Nguyen
Vince Yeh
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA35460B1 publication Critical patent/MA35460B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de formules (i) et (ii), et leurs compositions pharmaceutiques, qui sont utiles comme inhibiteurs de protéine kinase, ainsi que des procédés d'utilisation de tels composés pour traiter, améliorer ou prévenir un état associé à une activité de kinase anormale ou dérégulée. Dans certains modes de réalisation, l'invention concerne des procédés d'utilisation de tels composés pour traiter, améliorer ou prévenir des maladies ou des troubles qui impliquent une activation anormale de la kinase c-kit ou des kinases c-kit et pdgfr (pdgfr±, pdgfr²).
MA36864A 2011-09-01 2014-03-28 Composés et compositions en tant qu'inhibiteurs de kinase c-kit MA35460B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01
PCT/US2012/052802 WO2013033167A1 (fr) 2011-09-01 2012-08-29 Composés et compositions en tant qu'inhibiteurs de kinase c-kit

Publications (1)

Publication Number Publication Date
MA35460B1 true MA35460B1 (fr) 2014-09-01

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36864A MA35460B1 (fr) 2011-09-01 2014-03-28 Composés et compositions en tant qu'inhibiteurs de kinase c-kit

Country Status (30)

Country Link
US (3) US8569283B2 (fr)
EP (1) EP2751104B1 (fr)
JP (1) JP6134319B2 (fr)
KR (1) KR101962495B1 (fr)
CN (1) CN103797011B (fr)
AP (1) AP2014007493A0 (fr)
AR (1) AR087753A1 (fr)
AU (1) AU2012302042B2 (fr)
BR (1) BR112014004560A2 (fr)
CA (1) CA2845169C (fr)
CL (1) CL2014000492A1 (fr)
CO (1) CO6900141A2 (fr)
CR (1) CR20140107A (fr)
CU (1) CU20140024A7 (fr)
EA (1) EA026152B1 (fr)
ES (1) ES2761332T3 (fr)
GT (1) GT201400034A (fr)
IL (1) IL231227A0 (fr)
MA (1) MA35460B1 (fr)
MX (1) MX339937B (fr)
PE (1) PE20140909A1 (fr)
PH (1) PH12014500372A1 (fr)
PL (1) PL2751104T3 (fr)
PT (1) PT2751104T (fr)
SG (1) SG2014014369A (fr)
TN (1) TN2014000068A1 (fr)
TW (1) TW201313717A (fr)
UY (1) UY34301A (fr)
WO (1) WO2013033167A1 (fr)
ZA (1) ZA201401175B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP3007689B1 (fr) 2013-01-10 2018-03-07 Pulmokine, Inc. Inhibiteurs de kinase non sélectifs
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
UA125171C2 (uk) 2015-07-02 2022-01-26 Янссен Саєнсиз Айрленд Юсі Антибактеріальні сполуки
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
US20190256509A1 (en) * 2016-06-08 2019-08-22 Chrysalis, Inc. Histone demethylase inhibitors
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
US20200308169A1 (en) 2016-06-16 2020-10-01 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
KR20190121315A (ko) 2017-03-01 2019-10-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
WO2019090088A1 (fr) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulateurs de la voie de réponse intégrée au stress
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MA55976A (fr) * 2019-05-13 2022-03-23 Novartis Ag Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2021035788A1 (fr) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 Dérivé de pyrazole et son utilisation
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
TWI893032B (zh) 2019-12-13 2025-08-11 日商日本新藥股份有限公司 作為pdgf受體激酶抑制劑之化合物及組合物
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
MX2023010947A (es) 2021-03-16 2023-11-29 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (fr) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Composes antibacteriens
EP4423097A1 (fr) 2021-10-28 2024-09-04 Janssen Sciences Ireland Unlimited Company Amides d'imidazopyridine et composés apparentés destinés à être utilisés dans le traitement d'infections bactériennes
WO2024089170A1 (fr) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Composés antibactériens
JP2025540958A (ja) * 2022-11-30 2025-12-17 ブループリント メディシンズ コーポレイション 蕁麻疹の治療のための野生型ｃ－ｋｉｔキナーゼ阻害剤としてのＮ－フェニル－ピラゾロ［１，５－Ａ］ピリジン－３－カルボキサミド誘導体
WO2024123966A1 (fr) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Composés et compositions utilisés en tant qu'inhibiteurs de c-kit kinase
AU2023390239A1 (en) * 2022-12-07 2025-07-24 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (fr) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Composés antibactériens
WO2025072330A1 (fr) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Composés inhibiteurs de kit et leurs procédés d'utilisation
WO2025256552A1 (fr) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 Inhibiteur de dérivé pyrazole, son procédé de préparation et son utilisation
WO2025256609A1 (fr) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Formes cristallines d'un inhibiteur sélectif de kinase c-kit
WO2025259929A1 (fr) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Composés et compositions utilisés en tant qu'inhibiteurs de kinase c-kit

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
UA94570C2 (en) 2004-09-09 2011-05-25 Натко Фарма Лимитед Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
WO2006071940A2 (fr) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Modulateurs d'enzymes et traitements
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2008058037A1 (fr) * 2006-11-03 2008-05-15 Irm Llc Composés et compositions en tant qu'inhibiteurs des protéines kinases
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
US20150051206A1 (en) 2011-09-01 2015-02-19 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
KR20140105433A (ko) 2011-09-01 2014-09-01 아이알엠 엘엘씨 Pdgfr 키나제 억제제로서의 화합물 및 조성물
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Also Published As

Publication number Publication date
TW201313717A (zh) 2013-04-01
SG2014014369A (en) 2014-09-26
JP2014525448A (ja) 2014-09-29
US20140031333A1 (en) 2014-01-30
KR101962495B1 (ko) 2019-03-26
KR20140075692A (ko) 2014-06-19
JP6134319B2 (ja) 2017-05-24
US8569283B2 (en) 2013-10-29
EA026152B1 (ru) 2017-03-31
AU2012302042A1 (en) 2014-04-17
ES2761332T3 (es) 2020-05-19
CA2845169C (fr) 2022-04-19
US9023839B2 (en) 2015-05-05
CO6900141A2 (es) 2014-03-20
WO2013033167A1 (fr) 2013-03-07
EP2751104A1 (fr) 2014-07-09
UY34301A (es) 2013-04-05
CU20140024A7 (es) 2014-04-24
MX339937B (es) 2016-06-17
MX2014002484A (es) 2014-11-25
CL2014000492A1 (es) 2014-10-03
CN103797011A (zh) 2014-05-14
ZA201401175B (en) 2015-01-28
TN2014000068A1 (en) 2015-07-01
PH12014500372A1 (en) 2014-04-07
CR20140107A (es) 2014-05-02
BR112014004560A2 (pt) 2017-04-04
GT201400034A (es) 2015-02-19
US20140228347A1 (en) 2014-08-14
IL231227A0 (en) 2014-04-30
AR087753A1 (es) 2014-04-16
PL2751104T3 (pl) 2020-04-30
PE20140909A1 (es) 2014-07-20
CN103797011B (zh) 2016-03-30
EA201490545A1 (ru) 2014-07-30
US20130059832A1 (en) 2013-03-07
AP2014007493A0 (en) 2014-03-31
AU2012302042B2 (en) 2016-03-31
CA2845169A1 (fr) 2013-03-07
US8754071B2 (en) 2014-06-17
PT2751104T (pt) 2019-12-16
EP2751104B1 (fr) 2019-09-25

Similar Documents

Publication Publication Date Title
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA34948B1 (fr) Composes et procedes de modulation de kinase, et leurs indications
MA37739A1 (fr) Composés et compositions destinés à la modulation de l'activité de l'egfr
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MA40290A1 (fr) Agents immunorégulateurs
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA41179A (fr) Composés inhibiteurs de parg
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA30772B1 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MA34474B1 (fr) Agonistes de gpr40
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires